Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | CCR1 | P32246 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5759808 | 0.90 | ELANE (0.63) | ELANETP53CCR1HPGDNOTUM | |
| SCHEMBL5758927 | 0.90 | ELANE (0.58) | ELANETP53MAPTCCR1HPGD | |
| SCHEMBL5754710 | 0.90 | ELANE (0.67) | ELANETP53CCR1HPGDKDM4E | |
| SCHEMBL5760042 | 0.90 | ELANE (0.62) | ELANETP53CCR1NOTUMP2RX7 | |
| SCHEMBL5757507 | 0.89 | ELANE (0.66) | ELANETP53MAPTCCR1HPGD | |
| SCHEMBL5757948 | 0.88 | ELANE (0.65) | ELANETP53CCR1KDM4EALDH1A1 | |
| SCHEMBL5755122 | 0.87 | ELANE (0.67) | ELANETP53CCR1HPGDNOTUM | |
| SCHEMBL6214610 | 0.87 | ELANE (0.51) | ELANETP53MAPTLMNA | |
| SCHEMBL5757528 | 0.87 | ELANE (0.63) | ELANETP53MAPTHPGDKDM4E | |
| SCHEMBL5755788 | 0.86 | ELANE (0.79) | ELANEMAPTCCR1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562902-B1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | ASRAZENECA AB (SE) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | SERPINB1, ELANE, SERPINE1 | ELANE 2/4885TP53 3353/4885MAPT 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.